1. The clinical and economic impact of chronic venous insufficiency-associated lymphedema and the prevalence of persistent edema after venous intervention.
- Author
-
Genet, Matthew, Labropoulos, Nicos, Gasparis, Antonios, O'Donnell, Thomas, and Desai, Kush
- Subjects
- *
LYMPHEDEMA treatment , *LYMPHEDEMA , *MEDICAL care use , *ABLATION techniques , *T-test (Statistics) , *SCIENTIFIC observation , *FISHER exact test , *OUTPATIENT medical care , *TREATMENT effectiveness , *RETROSPECTIVE studies , *DESCRIPTIVE statistics , *SURGICAL stents , *CHI-squared test , *CHRONIC diseases , *VENOUS insufficiency , *COMPRESSION garments , *ECONOMIC aspects of diseases , *MEDICAL care costs , *CRITICAL care medicine , *DISEASE risk factors , *DISEASE complications ,LYMPHATIC massage - Abstract
Objectives: To determine the demographics, outcomes, and healthcare utilization of patients with chronic venous insufficiency-associated lymphedema (CVI-LED) and the prevalence of lymphedema-specific therapy use after venous intervention. Methods: The IBM MarketScan Commercial and Medicare Claims Databases were examined for patients with CVI-LED. Patient demographics and the use of lymphedema-specific therapy before and after venous intervention were collected. Results: Of 85,601 LED patients identified, 8,406 also had a diagnosis of CVI. In the CVI-LED group, 1051 underwent endovenous ablation or venous stent placement. The use of lymphedema-specific therapy before and after venous intervention was 52% and 39%, respectively (p <.05). The mean time of initiation of LED-specific therapy following venous intervention was 265 days after ablation and 347 days after stent placement. Conclusion: Treating venous hypertension improves certain venous-related signs and symptoms of CVI. However, a significant proportion of patients have persistent edema which may reflect underlying, sub-optimally treated LED. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF